Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opsens Inc T.OPS

OpSens Inc. is a medical device cardiology-focused company. The Company offers an advanced optical-based pressure guidewire that aims at improving the clinical outcome of patients with coronary artery disease. The Company’s segments include Medical and Industrial. The Medical segment focuses on physiological measurements, such as Fractional Flow Reserve (FFR) and Diastolic Pressure Ratio (dPR) in the coronary artery disease market and also supplies a range of miniature optical sensors to measure pressure and temperature to be used in a range of applications that can be integrated into other medical devices. The Industrial segment develops, manufactures and installs fiber optic sensing solutions for critical and demanding industrial applications. Its flagship product, the OptoWire, is a second-generation fiber optic pressure guidewire designed to provide the lowest drift in the industry and lesions access. It is approved for sale in the United States, European Union, Japan and Canada.


TSX:OPS - Post by User

Comment by Possibleidiot01on Apr 05, 2023 8:41pm
120 Views
Post# 35382252

RE:Bottom line assuming 15 procedures per day

RE:Bottom line assuming 15 procedures per dayI'm going to correct your math which should make your case look even better , 1460 x15 = 21,900.

You also seem to have missed this

"We are gaining positive traction in the U.S. and Canada with our proprietary 3-in-1 solution for TAVR procedures. Our sales team is operating at a high level as they educate cardiologists on the benefits of the SavvyWire to expand the number of accounts and drive adoption. Additionally, signing a GPO agreement last month with one of the largest group purchasing organizations in the United States and SavvyWire being featured in two live case broadcasts during the CRT conference is expected to drive continuous growth going forward," Mr. Laflamme concluded.


You're  saying everybody already knows about the product and how to use it which is highly debatable and that everybody had access to the product prior to the recent distribution agreement (which is untrue).

I'm open to hearing your response.
<< Previous
Bullboard Posts
Next >>